Expert Opinion

A Summary of the DACOTA Trial

By Dr. Chepsy Philip Believer's Church Medical College Hospital   Myeloproliferative - Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the…

2 years ago

Updated Results from the ASCEMBL Trial

By Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic   In the…

2 years ago

The Polarix Trial and the Rise of Polatuzumab-RCHP

By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center    Combination chemoimmunotherapy with the chemo regimen R-CHOP (Rituximab,…

2 years ago

Risk Factors for Relapse Among Breast Cancer Patients with Pathological Complete Response (pCR) Post Neoadjuvant Treatment

By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center   Attainment of pathological complete response (pCR) of breast cancer is…

2 years ago

Oral SERD Elacestrant is now an option for metastatic hormone-receptor positive breast cancer: Findings from the Phase III EMERALD Trial

By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center   Endocrine therapy is the mainstay of the management of hormone…

2 years ago

Neoadjuvant-Adjuvant or Adjuvant Only Pembrolizumab in Advanced Melanoma

By Dr. Radhika Kulkarni Henry Ford Cancer Institute   On March 2nd, 2023, results of the Phase 2 trial, SWOG…

2 years ago

CheckMate-722: Nivolumab plus Chemotherapy versus Chemotherapy in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer with Disease Progression after EGFR Tyrosine Kinase Inhibitors

By Dr. Dipesh Uprety Karmanos Cancer Institute   While immunotherapy is being used religiously for non-oncogene-addicted advanced non-small cell lung…

2 years ago

De-escalating Therapy in Human Papillomavirus-Related Oropharyngeal Cancer

By Dr. Tarik Hadid Wayne State University   Human papillomavirus (HPV) is a small DS-DNA virus, and humans are the…

2 years ago

The CALYPSO Study Tests the Combination of MET and PD-L1 Inhibition in Patients with Advanced Papillary Renal Cancer

By Dr. Inas Abuali Massachusetts General Hospital   There is a paucity of available treatment options for patients with advanced…

2 years ago

AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia

Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic   In the phase…

2 years ago